Calamos Wealth Management LLC Has $16.98 Million Stock Holdings in Danaher Corporation $DHR

Calamos Wealth Management LLC raised its holdings in shares of Danaher Corporation (NYSE:DHR) by 41.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 85,624 shares of the conglomerate’s stock after acquiring an additional 24,888 shares during the period. Calamos Wealth Management LLC’s holdings in Danaher were worth $16,976,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Ceredex Value Advisors LLC raised its holdings in Danaher by 1.6% in the second quarter. Ceredex Value Advisors LLC now owns 249,377 shares of the conglomerate’s stock worth $49,262,000 after purchasing an additional 3,862 shares during the period. Chicago Capital LLC increased its position in shares of Danaher by 11.6% in the 2nd quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock valued at $2,634,000 after buying an additional 1,391 shares in the last quarter. Weitz Investment Management Inc. lifted its holdings in Danaher by 6.1% during the second quarter. Weitz Investment Management Inc. now owns 526,950 shares of the conglomerate’s stock worth $104,094,000 after acquiring an additional 30,300 shares in the last quarter. UniSuper Management Pty Ltd grew its stake in Danaher by 1.6% in the first quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock valued at $34,954,000 after acquiring an additional 2,667 shares during the period. Finally, Nvwm LLC grew its stake in Danaher by 20.4% in the second quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock valued at $1,401,000 after acquiring an additional 1,204 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 21,776 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president owned 14,553 shares in the company, valued at $3,190,454.19. This trade represents a 59.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the transaction, the senior vice president owned 2,625 shares in the company, valued at $552,352.50. This represents a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 30,248 shares of company stock valued at $6,609,663. 11.20% of the stock is currently owned by corporate insiders.

Danaher Trading Up 0.1%

Shares of NYSE:DHR opened at $230.76 on Wednesday. The company’s 50-day moving average price is $223.31 and its two-hundred day moving average price is $208.61. Danaher Corporation has a one year low of $171.00 and a one year high of $258.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The stock has a market capitalization of $162.99 billion, a PE ratio of 47.58, a price-to-earnings-growth ratio of 4.46 and a beta of 0.89.

Danaher (NYSE:DHR) last released its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. During the same quarter in the previous year, the business earned $1.71 earnings per share. Danaher’s quarterly revenue was up 4.4% on a year-over-year basis. On average, equities analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, December 26th. Danaher’s payout ratio is presently 26.39%.

Wall Street Analysts Forecast Growth

DHR has been the topic of several recent analyst reports. Robert W. Baird set a $247.00 price objective on Danaher in a report on Wednesday, October 22nd. Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Bank of America dropped their price objective on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Jefferies Financial Group upped their target price on shares of Danaher from $245.00 to $255.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Finally, The Goldman Sachs Group assumed coverage on Danaher in a research note on Tuesday, December 9th. They issued a “buy” rating and a $265.00 price target on the stock. Twenty-one equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $248.25.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.